Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way - 2As nations push for more ambition at climate talks, chairman says they may get it
- 3Hundreds of kilos of protected plant seized by Israel Nature and Parks Authority in Golan
- 4A decade after Brazil’s deadly dam collapse, Indigenous peoples demand justice on the eve of COP30
- 5The Main 20 Gaming Control center Ever
- Step by step instructions to Pick A Keep money with High Fixed Store Loan costs
- 6 Web-based Staple Help You Can Trust
- Best Food Truck Cooking: Decision in favor of Your Number one!
- Misremembering might actually be a sign your memory is working optimally
- How a Snake That Eats Cobras Redefined the Meaning of ‘King’
- From Educational Loans to Obligation Free: Independence from the rat race Accomplished
- Extravagance SUVs for Seniors: Solace, Innovation, and Security
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
- Step by step instructions to Analyze Senior Insurance Contracts Really.
